Mostrar el registro sencillo del ítem

dc.contributor.author
Fabbri, Margherita  
dc.contributor.author
Perez Lloret, Santiago  
dc.contributor.author
Rascol, Olivier  
dc.date.available
2022-10-11T13:58:01Z  
dc.date.issued
2020-11  
dc.identifier.citation
Fabbri, Margherita; Perez Lloret, Santiago; Rascol, Olivier; Therapeutic strategies for Parkinson’s disease: Promising agents in early clinical development; Taylor & Francis Ltd; Expert Opinion on Investigational Drugs; 29; 11; 11-2020; 1249-1267  
dc.identifier.issn
1354-3784  
dc.identifier.uri
http://hdl.handle.net/11336/172482  
dc.description.abstract
Introduction: To date, no drug has demonstrated clinically indisputable neuroprotective efficacy in Parkinson’s disease (PD). We also have no effective symptomatic treatment for disabling symptoms such as balance problems, and dementia, and we need to improve the efficacy and safety profile of drugs currently used in the management of motor complications. Areas covered: We examine the agents which appear to have most therapeutic promise based on concepts, feasibility in a reasonable time frame, and available clinical data and place an emphasis on disease-modifying treatments. PUBMED and Clinicaltrials.gov databases were searched for Phase I and II randomized trials for symptomatic or disease-modifying treatments considering only studies that began since 2010 or that were completed after 2015, up to 30 April 2020. Expert opinion: Encouraging progress has been made in our understanding of molecular pathways. We find passive immunization approaches against α-synuclein, LRRK2 kinase inhibitors, and treatment that can increase GCase activity, which have shown some efficacy on both GBA-mutated and non-mutated PD patients. The recognition of non-dopaminergic impairment and the prominent role of non-motor symptoms have prompted the development of trials on compounds that could tackle different neurotransmitter systems. Future approaches will encompass more personalized medicine strategies based on molecular signatures and non-motor phenotypes.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Taylor & Francis Ltd  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
CLINICAL TRIALS  
dc.subject
DISEASE-MODIFYING  
dc.subject
DOPAMINERGIC TREATMENT  
dc.subject
NON-DOPAMINERGIC TREATMENT PARKINSON’S DISEASE  
dc.subject
PERSONALIZED MEDICINE  
dc.subject
SYMPTOMATIC TREATMENT  
dc.subject.classification
Farmacología y Farmacia  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Therapeutic strategies for Parkinson’s disease: Promising agents in early clinical development  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2022-10-03T17:51:42Z  
dc.identifier.eissn
1744-7658  
dc.journal.volume
29  
dc.journal.number
11  
dc.journal.pagination
1249-1267  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Fabbri, Margherita. Universite Paul Sabatier Toulouse III; Francia  
dc.description.fil
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina  
dc.description.fil
Fil: Rascol, Olivier. Universite Paul Sabatier Toulouse III; Francia  
dc.journal.title
Expert Opinion on Investigational Drugs  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/13543784.2020.1814252  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1814252